SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31

China SXT Pharmaceuticals, Inc.

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026

$0.11+0.05 (+71.08%)

Close on Oct 19, 2026

Community

Notes and questions about China SXT Pharmaceuticals from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in China SXT Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-80 reverse split on Aug 10, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SXTC.

Revenue growth-34.6% · median -11.0%

Gross margin21.9% · median 9.0%

Operating margin-625.9% · median -1089.8%

Net margin-545.2% · median -114.3%

Advertisement
300 × 250